Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | The ECOG-ACRIN E2810 study: pazopanib for patients with mRCC

Elizabeth Plimack • 3 Jun 2019
ASCO 2019
Genitourinary Cancer Kidney Cancer Pazopanib
ECOG-ACRIN E2810

Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center, Philadelphia, PA talks about The ECOG-ACRIN E2810 (NCT01575548) study that looks at pazopanib for patients with metastatic renal cell carcinoma (mRCC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Elizabeth Plimack

3:54
Guadecitabine + atezolizumab in mUC who have progressed after initial checkpoint inhibitor therapy
Elizabeth Plimack • 7 Apr 2021
1:41
Molecular profiling of exceptional responders to cancer therapy
Elizabeth Plimack • 7 Apr 2021
0:57
Areas of unmet need for patients with advanced UC
Elizabeth Plimack • 7 Apr 2021
2:22
JAVELIN Bladder 100: practice-changing data
Elizabeth Plimack • 1 Jun 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals